Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TELO |
---|---|---|
09:32 ET | 110 | 6.77 |
09:43 ET | 100 | 6.735 |
09:56 ET | 100 | 6.6776 |
09:59 ET | 100 | 6.6 |
10:14 ET | 100 | 6.72 |
10:17 ET | 985 | 6.71 |
10:28 ET | 500 | 6.7 |
10:44 ET | 100 | 6.645 |
11:00 ET | 2241 | 6.555 |
11:02 ET | 1400 | 6.51 |
11:04 ET | 400 | 6.5695 |
11:06 ET | 300 | 6.5839 |
11:08 ET | 482 | 6.6 |
11:26 ET | 100 | 6.52 |
11:27 ET | 300 | 6.5677 |
11:29 ET | 6212 | 6.41 |
11:36 ET | 1186 | 5.91 |
11:58 ET | 200 | 6.1036 |
12:05 ET | 100 | 6.22 |
12:16 ET | 100 | 6.29 |
12:43 ET | 300 | 6.19 |
12:48 ET | 300 | 6.19 |
01:01 ET | 500 | 6.1764 |
01:26 ET | 100 | 6.11 |
01:44 ET | 100 | 6.315 |
01:50 ET | 211 | 6.3857 |
02:09 ET | 192 | 6.385 |
02:13 ET | 100 | 6.395 |
02:29 ET | 1918 | 6.23 |
02:33 ET | 100 | 6.19 |
02:45 ET | 100 | 6.395 |
03:12 ET | 100 | 6.39 |
03:18 ET | 899 | 6.4 |
03:25 ET | 100 | 6.41 |
03:36 ET | 100 | 6.865 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Telomir Pharmaceuticals Inc | 203.3M | -14.3x | --- |
ASP Isotopes Inc | 168.3M | -6.9x | --- |
Biostem Technologies Inc | 147.6M | 0.0x | --- |
Hongchang International Co Ltd | 115.5M | -258.8x | --- |
Jasper Therapeutics Inc | 307.3M | -3.3x | --- |
Cellectar Biosciences Inc | 97.7M | -0.9x | --- |
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Company’s BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $203.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.48 |
Book Value | $0.12 |
P/E Ratio | -14.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.